procarbazine has been researched along with Lymphoma, Mantle-Cell in 4 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Lymphoma, Mantle-Cell: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruan, J | 3 |
| Martin, P | 3 |
| Coleman, M | 3 |
| Furman, RR | 1 |
| Cheung, K | 1 |
| Faye, A | 1 |
| Elstrom, R | 3 |
| Lachs, M | 1 |
| Hajjar, KA | 1 |
| Leonard, JP | 2 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Engert, A | 1 |
| Furman, R | 2 |
| Niesvizky, R | 2 |
| George, P | 2 |
| Leonard, J | 1 |
| Kaufmann, T | 1 |
| Kaufman, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma[NCT00151281] | Phase 2 | 25 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II, Single-arm, Open-label, Muti-center Study[NCT02879526] | Phase 2 | 45 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Stromal angiogenesis was assessed using blood vascular and perivascular markers, including VEGFR-1, VEGFR-2, CD34, and a-SMA, as well as lymphatic vascular markers ofVEGFR-3, podoplanin, and Lyve-1. (NCT00151281)
Timeframe: 38 months
| Intervention | pg/mL (Median) |
|---|---|
| RT-PEPC Drug Therapy | 109.5 |
measured by overall Response Rate (ORR), which includes Complete response and partial response. (NCT00151281)
Timeframe: 38 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment Arm | 73 |
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. (NCT00151281)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 or 4 neutropenia | Anemia | Thrombocytopenia | Fatigue | Constipation | Cough | Nausea | Neuropathy | Dyspnea | Rash | |
| RT-PEPC Drug Therapy | 14 | 1 | 4 | 22 | 14 | 14 | 13 | 13 | 11 | 10 |
"QoL assessments were obtained with version 3 of the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. The FACT-G is comprised of four subscales: physical well-being (7-items, score range 0-28), social/family well-being (7-items, score range 0-28), emotional well-being (6-items, score range 0-24), and functional well-being (7-items, score range 0-28). Users of the FACT-G are able to generate an overall score and four subscale scores with ranges and distributions that are sample-specific. All questions in the FACT-G use a 5-point rating scale (0 = Not at all to 4 = Very much) A higher number indicates a better Quality of Life, and has a possible range of 0-108 points.~ANOVA was used to compare the difference in the means of total score among the different time points (baseline, every 2M until 6M, and every 6M until PD). The mean of the total FACT-G scores at baseline and mean of total score at all timepoints (using ANOVA) are reported below." (NCT00151281)
Timeframe: baseline, every 2 months until Month 6, and every 6 months until disease progression
| Intervention | FACT-G score (Mean) | |
|---|---|---|
| Mean FACT-G Score at baseline | Mean Total FACT-G Score between all time points | |
| RT-PEPC Drug Therapy | 83.3 | 89.4 |
1 review available for procarbazine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
2 trials available for procarbazine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Respons | 2008 |
1 other study available for procarbazine and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Leukocyte Count | 2008 |